Professional Essentials · Free · No registration
Non-radiographic axial spondyloarthritis
Establish the diagnosis, interpret MRI in context and treat supported inflammation without waiting for radiographic progression.
Non-radiographic axial spondyloarthritis (nr-axSpA) describes axSpA without definite sacroiliitis at the conventional radiographic threshold. It does not mean mild disease, a normal MRI, a recent onset or an inevitable preliminary stage of ankylosing spondylitis. The useful clinical record separates diagnostic confidence, current inflammation, structural findings and functional impact.
1. Establish the clinical diagnosis
Reconstruct symptom onset and evolution, distinguishing age at onset from age at consultation. Inflammatory-pattern back pain, alternating buttock pain, documented uveitis, psoriasis, inflammatory bowel disease, peripheral arthritis, enthesitis and family history can support the assessment. Verify reported manifestations: any red eye is not automatically uveitis, and heel tenderness does not establish inflammatory enthesitis.
NICE NG65 cautions that negative HLA-B27 and normal inflammatory markers do not independently exclude disease. Conversely, positive HLA-B27 or a good NSAID response cannot establish it. Consider mechanical pain, hip disease, osteitis condensans ilii, fracture, infection and coexisting widespread pain. Multiple negative findings still affect probability; “does not exclude” should not become “does not matter.”
Keep referral, classification and diagnosis distinct. ASAS classification criteria support research recruitment; the 2025 BSR guideline warns against using them as a diagnostic checklist. If uncertainty remains, name the unresolved finding and how reassessment could change the conclusion.
Diagnostic reasoning and competing explanations → Professional access required
2. Read the complete imaging pattern
The 2026 ACR/SAA/SPARTAN posted summary conditionally favors AP pelvic radiography first in adults, followed by dedicated sacroiliac MRI without contrast when radiographs are nondiagnostic. A lumbar MRI cannot substitute for an appropriately acquired sacroiliac examination. The ASAS–SPARTAN acquisition consensus specifies at least four sequences in two planes, assessing inflammation, structural damage and the bone–cartilage interface.
Interpret marrow edema alongside its distribution, depth, extent and accompanying erosions, fat lesions or backfill. Postpartum and loading-related abnormalities can mimic inflammatory sacroiliitis. In a prospective pregnancy cohort, 41% met the study’s ASAS MRI definition at twelve months postpartum; this was not an axSpA prevalence estimate.
Record childbirth, physical loading, prior imaging and treatment exposure. A quiet treated scan does not erase previous disease, while a technically adequate negative examination remains relevant evidence. Seek expert review for consequential discordance; repeat imaging to answer a defined question, not simply until a positive result appears.
Imaging protocols, structural lesions and mimics → Professional access required
3. Separate activity from prognosis
Measure inflammatory activity, pain, fatigue, function and participation separately. ASDAS combines patient responses with an inflammatory marker; BASDAI reflects symptoms, BASFI function. No score independently establishes that all residual pain is inflammatory. Check laboratory units and compare the same instrument over time.
Radiographic progression is one outcome, not the definition of an important disease burden. In PROOF, 40 of 246 participants with eligible follow-up imaging progressed at some point during five years. Selection, treatment and reading variability limit individual prediction. Do not promise either inevitable fusion or permanent absence of damage. Treat current supported disease and follow meaningful functional goals.
Fatigue deserves its own assessment rather than being hidden inside a global score. Ask about sleep, mood, anemia, medication effects and the activities the person has stopped doing. EULAR fatigue recommendations support tailored physical activity and psychoeducational interventions, with immunomodulatory change when clinically indicated. A quieter inflammatory assessment should lead to a broader plan for persistent symptoms, not dismissal. Document whether improvement reflects restored participation or simply avoiding demanding activities.
Natural history and limits of prognosis → Professional access required
4. Build an effective treatment plan
Begin individualized exercise, mobility work and rehabilitation alongside medication when indicated. Agree on a practical target, such as sleeping through the night or tolerating a work shift. A purposeful NSAID trial records dose, duration, benefit and toxicity; assess gastrointestinal, kidney and cardiovascular risks. Do not combine systemic NSAIDs or require unsafe exposure to satisfy a sequence.
The ASAS–EULAR framework supports targeted therapy for persistently active disease despite appropriate initial care, incorporating ASDAS ≥2.1 and objective evidence. In nr-axSpA, that evidence generally means attributable CRP elevation and/or convincing MRI inflammation. Conventional DMARDs are not obligatory trials for purely axial disease; peripheral arthritis may justify a separate indication. Long-term systemic glucocorticoids are unsuitable maintenance therapy for axial inflammation.
The 2026 ACR summary places TNF and IL-17 inhibitors on equal footing as initial biologic classes, generally ahead of JAK inhibitors. Check the exact local indication. For example, US upadacitinib labeling requires objective inflammation and inadequate response or intolerance to TNF-blocker therapy. A class recommendation does not approve every molecule for nr-axSpA.
Direct trials demonstrate benefit without guaranteeing remission. In BE MOBILE 1, bimekizumab produced ASAS40 responses in 47.7% versus 21.4% with placebo at week sixteen. That comparison does not establish superiority over other targeted treatments or prevention of eventual radiographic progression.
Treatment evidence, eligibility and preparation → Professional access required
5. Match therapy to the whole patient
Recurrent uveitis generally favors monoclonal TNF targeting; significant psoriasis may favor IL-17 inhibition. Active bowel disease requires a molecule and regimen effective for the specific bowel condition. Do not initiate IL-17 inhibition in active IBD. These BSR recommendations require organ-specific assessment, not a single generic “SpA drug” choice.
Screen for relevant infections, review vaccination and reconcile medications before starting treatment. Consider drug-specific infection, cardiac, neurological, hepatic and reproductive precautions. Upadacitinib’s boxed warnings include serious infection, malignancy, cardiovascular events and thrombosis; convenient oral administration does not remove these risks.
EULAR infection guidance recommends latent tuberculosis screening before biologic or targeted synthetic therapy and establishing hepatitis B status before immunosuppression. Positive results require a defined prevention or treatment pathway. Record who reviews screening results, required laboratory monitoring and new symptoms. A normal CRP is not a drug-safety assessment, and normal safety laboratories do not establish inflammatory remission.
Discuss pregnancy before an avoidable interruption. The EULAR reproductive update permits all TNF inhibitors throughout pregnancy after individualized assessment. Preserve effective control while planning obstetric follow-up, postpartum care and exposure-specific infant vaccination.
Choosing therapy for eye, skin and bowel disease → Professional access required
6. Review, reassess and taper carefully
Assess targeted-treatment response around three to four months, sooner for toxicity or deterioration. Compare actual treatment exposure, inflammatory findings, function and agreed goals. Distinguish primary nonresponse, secondary loss of response and persistent symptoms from other mechanisms before switching.
Make the next decision explicit: continue an effective regimen, correct an interruption, investigate discordant findings or change treatment for verified residual inflammation. A patient whose pain improved but whose uveitis recurs has a different problem from one with no response in any domain. Preserve useful benefits while addressing what remains uncontrolled.
With sustained control, consider a shared, monitored reduction with a review date and rescue plan. C-OPTIMISE supports dose reduction in selected responders more strongly than complete withdrawal; it does not validate arbitrary schedules for every drug. Specify whether the proposed regimen is off-label. A painful photophobic red eye requires same-day eye assessment; new bladder dysfunction or saddle sensory change requires emergency evaluation.
Monitoring, residual symptoms and tapering → Professional access required
Selected sources
- ACR/SAA/SPARTAN 2026 axial SpA guideline summary. Posted June 24, 2026; summary-stage status verified October 4, 2026.
- ASAS–EULAR management recommendations, 2022 update.
- BSR targeted-therapy guideline, 2025.
- NICE NG65: diagnosis and management.
- ASAS–SPARTAN diagnostic sacroiliac MRI protocol, 2024.
- Kiil et al. Serial sacroiliac MRI during pregnancy and postpartum, 2023.
- Poddubnyy et al. PROOF five-year observational study, 2024.
- BE MOBILE randomized trials, 2023.
- C-OPTIMISE randomized dose-reduction study, 2020.
- EULAR reproductive recommendations: 2024 update, published 2025.
The official ASDAS instrument and current US prescribing information are linked at the relevant statements.